Form 8-K Jazz Pharmaceuticals For: Aug 07
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/19/2026
- Tech selloff weighs down Wall Street as bond yields climb
- Baidu slips as Q2 results miss estimates despite growth in AI cloud business
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
- Home Depot beats estimates, reaffirms fiscal 2026 guidance
- Citi says positioning risk is shifting from short squeezes to profit-taking
- Tech selloff weighs down Wall Street as bond yields climb
- Francisco Partners to acquire Weave Communications for $650M
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
- Goldman Sachs to acquire real estate company LCN for up to $410M
- BofA raises hyperscaler AI capex outlook to $3.6tn through 2028
Jazz Pharmaceuticals (JAZZ) PT Raised to $206 at BMO Capital
August 8, 2018 7:00 AM EDTBMO Capital raised its price target on Jazz Pharmaceuticals (NASDAQ: JAZZ) to $206.00 (from $201.00) while maintaining a Outperform rating.
Analsyt Gary Nachman commented, 'JAZZ reported a solid top and bottom line beat with 2Q revenue of $501mm vs. BMO/consensus $466mm/$470mm, and adj. EPS... More
